HYPERPARATHYROIDISM PRIMARY

This adverse event was reported 365 times

These drugs are most commonly taken by patients reporting HYPERPARATHYROIDISM PRIMARY:

# Drug Count
0 DENOSUMAB 37
1 LITHIUM CARBONATE 35
2 ALENDRONATE SODIUM 33
3 FUROSEMIDE 28
4 METHOTREXATE SODIUM 27
5 ERGOCALCIFEROL 24
6 METHOTREXATE 24
7 CINACALCET HYDROCHLORIDE 18
8 ASPIRIN 16
9 ASPIRIN 325 MG 16
See all common drugs associated with HYPERPARATHYROIDISM PRIMARY

HYPERPARATHYROIDISM PRIMARY is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 SODIUM IODIDE I 123 4 0.0043
1 SODIUM IODIDE I 131 4 0.0042
2 ISRADIPINE 2 0.0036
3 ALENDRONATE SODIUM AND CHOLECALCIFEROL 7 0.0025
4 AMILORIDE HYDROCHLORIDE 2 0.0023
5 LITHIUM CARBONATE 35 0.0020
6 CARBOXYMETHYLCELLULOSE SODIUM, GLYCERIN AND POLYSORBATE 80 1 0.0018
7 BARICITINIB 4 0.0013
8 CALCITONIN SALMON 4 0.0013
9 DIFLUPREDNATE OPHTHALMIC 1 0.0011
See all drugs enriched for association with HYPERPARATHYROIDISM PRIMARY

HYPERPARATHYROIDISM PRIMARY is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Interleukin-5 Antagonist [EPC] 1 0.0015
1 Calcitonin [EPC] 4 0.0013
2 Provitamin D2 Compound [EPC] 24 0.0008
3 Vitamin D3 Analog [EPC] 7 0.0003
4 Oxytocic [EPC] 1 0.0003
5 Chloride Channel Activator [EPC] 2 0.0002
6 Thyroid Hormone Synthesis Inhibitor [EPC] 2 0.0002
7 RANK Ligand Inhibitor [EPC] 37 0.0002
8 Typical Antipsychotic [EPC] 4 0.0002
9 CD52-directed Cytolytic Antibody [EPC] 3 0.0002
See all drug classes enriched for association with HYPERPARATHYROIDISM PRIMARY